# Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites

> **NCT07096440** · — · NOT_YET_RECRUITING · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 105 (estimated)

## Conditions studied

- Allergic Rhinitis Due to House Dust Mite
- Allergic Conjunctivitis Due to Dermatophagoides Farinae
- Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus
- Allergic Asthma Due to Dermatophagoides Farinae
- Allergic Asthma Due to Dermatophagoides Pteronyssinus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07096440
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096440, "Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07096440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*